Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 297Rituximab 272Etoposide 149Filgrastim 142fludarabine phosphate 120Cytarabine 109Vincristine 107Melphalan 102Radiotherapy 101Doxorubicin 97Peripheral Blood Stem Cell Transplantation 93Methotrexate 91fludarabine 86Prednisone 86Busulfan 86Tacrolimus 66Mycophenolic Acid 62Granulocyte Colony-Stimulating Factor 60Antilymphocyte Serum 58Dexamethasone 57Whole-Body Irradiation 55Carmustine 54Bortezomib 45Cyclosporine 44Lenalidomide 41Methylprednisolone 40sargramostim 39Bendamustine Hydrochloride 37ibritumomab tiuxetan 34Ifosfamide 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma × pidilizumab × Clear all
NCT00904722 2016-06-03

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
32 enrolled 4 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡